Aviado · Research
Longevity Daily
Wednesday, June 10, 2026
Listen
Today's Brief
Today's most important story: a 12-year AI analysis links glucosamine — one of the world's most popular joint supplements — to a 25% higher risk of progressing from mild cognitive impairment to Alzheimer's disease, a finding every health optimizer needs to know. The FDA meanwhile has ruled NMN is not a dietary ingredient, sending shockwaves through the NAD+ supplement market. History is being made in longevity medicine as Life Biosciences doses its first human patient in an FDA-cleared epigenetic reprogramming trial. And a 9-year study delivers a counterintuitive finding: extreme-intensity HIIT may actually accelerate brain shrinkage in older adults.
10 stories8 peer-reviewed1 trials
Cognitive Health & Neuroprotection
The Joint Supplement Millions Take May Accelerate Alzheimer's Progression
Analyzing 12 years of de-identified patient records with AI, researchers found that glucosamine users with mild cognitive impairment face a 25% higher likelihood of progressing to full Alzheimer's disease — and that glucosamine use among people already diagnosed with Alzheimer's is associated with a 25% spike in mortality risk. Glucosamine is one of the most commonly taken OTC supplements, particularly among older adults managing joint pain, making this one of the most practically significant supplement safety findings in years. This is a large observational study and does not prove causation, but the size and scope of the dataset — 12 years of real-world records — make it hard to dismiss. If you or someone you care for takes glucosamine and has any cognitive concerns, this finding warrants an honest conversation with a physician.
Read more →Extreme HIIT May Shrink the Aging Brain, 9-Year Study Finds
A 9-year longitudinal study tracking older adults found that those who pushed exercise to maximum heart rate showed greater brain volume loss over time compared to those exercising at moderate intensity — a striking reversal of the 'harder is better' HIIT narrative. The findings suggest that for older brains, sustained moderate-intensity exercise may be more neuroprotective than all-out intervals. The study specifically followed older adults; implications for younger exercisers remain less established.
Read more →Supplements & Compounds
Low-Dose Continuous Rapamycin Tames Neuroinflammation Without Broad Immunosuppression
A new PLOS ONE study found that continuous low-dose rapamycin — mixed into food rather than taken in weekly pulses — selectively suppressed pro-inflammatory IL-17-producing immune cells and reduced neuroinflammation markers in aging mice, without the widespread immune suppression seen at transplant doses. For the growing community of longevity enthusiasts using off-label rapamycin, this adds mechanistic weight to the idea that the drug's anti-aging effects work partly through targeted immune modulation, not broad suppression. This remains a mouse study, and the optimal dosing regimen in humans is still an open question.
Read more →Semaglutide May Slow Biological Aging — Well Beyond Its Weight-Loss Benefits
A post-hoc analysis of a semaglutide trial in people living with HIV found that the GLP-1 drug significantly slowed biological aging markers, pointing to anti-aging effects that go far beyond weight and glucose control. This is one of the first human datasets to link a GLP-1 receptor agonist to direct aging biology, adding fuel to the growing interest in semaglutide as a longevity tool. Crucial caveat: this is a post-hoc analysis from an HIV-specific trial population, so extrapolating these findings to healthy people using Ozempic or Wegovy for weight management is premature.
Read more →Research & Papers
Metformin Reverses Intestinal Aging in Primates by Restoring a Key Protein
A Nature Aging study used single-nucleus sequencing to map how the intestinal lining ages in primates, identifying a decline in the protein NCoR1 as a central driver — and then demonstrating that metformin restores NCoR1 levels and measurably delays intestinal aging in non-human primates. This is the first time metformin's geroprotective effects have been mapped at single-cell resolution in a primate model, providing a concrete mechanistic bridge between animal data and human biology. Given that gut aging drives systemic inflammation and impairs nutrient absorption, this finding strengthens the case for metformin as a broad-spectrum anti-aging intervention.
Read more →Metabolically Unhealthy and Overweight? You May Be Aging Nearly 4 Years Faster
An analysis of 8,986 U.S. adults from the NHANES cohort found that people who were both metabolically unhealthy and overweight or obese showed 3.70 years of accelerated biological aging compared to metabolically healthy normal-weight peers — the largest effect among four phenotype groups. Even metabolically healthy overweight or obese individuals showed 1.91 years of accelerated aging, making clear that 'healthy obesity' still carries real biological cost. The finding reframes the obesity-aging relationship: metabolic dysfunction is the primary driver, not excess weight alone.
Read more →Can Your Wearable Really Tell You Your Biological Age? Science Says Not Quite
A new JMIR analysis examines whether the biological age estimates served up by consumer wearables hold up to scientific scrutiny — and finds the evidence mixed at best. While some devices show correlations with known aging markers, the field lacks standardized validation and marketing claims consistently outpace the underlying science. If you're tracking your biological age with a ring or watch, treat the number as a rough trend indicator rather than a clinical measurement.
Read more →Lifestyle & Nutrition
Just 90–120 Minutes of Strength Training Weekly Cuts Premature Death Risk by 13%
A large Harvard-led study analyzing data from over 99,000 adults found that roughly 90–120 minutes of resistance training per week — about two focused sessions — was associated with a 13% lower risk of premature death, with benefits plateauing beyond that dose. The research adds much-needed precision to the dose-response question: a moderate commitment to strength training delivers significant longevity returns, and grinding out more isn't necessary. Combining resistance training with aerobic exercise appeared to offer the greatest overall benefit.
Read more →Industry & Policy
World First: Epigenetic Reprogramming Therapy Dosed in a Human Patient
Life Biosciences has dosed its first patient in a Phase 1 trial of ER-100, a gene therapy delivering partial Yamanaka factor reprogramming to reverse age-related damage in optic neurons — targeting glaucoma and optic neuropathy as the entry point. This is the world's first FDA-cleared human trial of partial epigenetic reprogramming, a technology that reversed vision loss in mice with damaged optic nerves in a landmark 2020 Nature study. While initial endpoints focus on safety and tolerability, researchers across the longevity field are watching closely: a clean safety signal here could open the door to reprogramming therapies far beyond the eye.
Read more →FDA Rules NMN Is Not a Dietary Ingredient — A Regulatory Earthquake for NAD+ Supplements
The FDA has officially determined that beta-NMN (nicotinamide mononucleotide) does not qualify as a dietary ingredient under the FD&C Act's drug preclusion clause, because NMN was investigated as a pharmaceutical before it entered the supplement market. This ruling clears a regulatory path for pharmaceutical companies to develop NMN as a drug — but puts the existing NMN supplement market, worth hundreds of millions annually, in serious legal jeopardy. Products currently on shelves aren't subject to immediate recall, but manufacturers face a rapidly shifting enforcement environment that makes NMN a risky ingredient going forward.
Read more →